Jessie English
Director/Board Member bei SENSEI BIOTHERAPEUTICS, INC.
Vermögen: 9 379 $ am 31.03.2024
Profil
Jessie M.
English is an Independent Director at Sensei Biotherapeutics, Inc. She previously held positions as a Senior Director at IRBM SpA and Merck Research Laboratories Massachusetts LLC from 2008 to 2010.
In 2018 to 2019, she served as the Chief Scientific Officer at Tilos Therapeutics, Inc. Dr. English was also the Head-Research at Belfer Center for Applied Cancer Science.
She was the Vice President-Kinase Biology at ArQule, Inc. from 2010 to 2011 and the VP & Head-Discovery Research at EMD Serono, Inc. from 2016 to 2018.
Currently, she is also the Chief Scientific Officer at Bakx Therapeutics, Inc. Dr. English completed her undergraduate degree at Kansas State University and holds a doctorate from The University of North Carolina at Chapel Hill.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
10.07.2023 | 8 932 ( 0,04% ) | 9 379 $ | 31.03.2024 |
Aktive Positionen von Jessie English
Unternehmen | Position | Beginn |
---|---|---|
SENSEI BIOTHERAPEUTICS, INC. | Director/Board Member | 01.04.2021 |
Ehemalige bekannte Positionen von Jessie English
Unternehmen | Position | Ende |
---|---|---|
Bakx Therapeutics, Inc.
Bakx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bakx Therapeutics is a company based in DE that focuses on developing more effective and precise therapeutics that utilize the mitochondrial apoptosis pathway. The American company's proprietary codynx™ drug discovery platform integrates computational and experimental capabilities to collaborate with researchers in validated biological pathways. Bakx's leading asset, partnered with Ipsen, is focused on activating the bax protein to treat cancer and age-related diseases. Bakx Therapeutics, Inc. was co-founded by world-leading researchers in apoptosis and computationally aided drug discovery. Sree Kant has been the CEO of the company since 2020. | Chief Tech/Sci/R&D Officer | 01.11.2022 |
Tilos Therapeutics, Inc.
Tilos Therapeutics, Inc. BiotechnologyHealth Technology Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA. | Chief Tech/Sci/R&D Officer | 01.11.2019 |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | 01.01.2018 |
ARQULE, INC. | Corporate Officer/Principal | 01.01.2011 |
IRBM SpA
IRBM SpA BiotechnologyHealth Technology IRBM SpA is a research organization that specializes in drug discovery and development. IRBM is based in Pomezia, IT, and has subsidiaries in Italy. The Italian company produces recombinant proteins in a homogeneous state and use cyclization to pre-organize compounds for target binding. The private company uses nuclear magnetic resonance (NMR) spectroscopy to study structural biology, clinical research solutions, functional genomics, structure/activity relationships, drug discovery, macromolecule, and small-molecule analysis. The company has a screening library of over 320,000 compounds and use virtual screening and NMR to drive innovation. The company was founded in 2010 by Piero di Lorenzo, who has been the CEO since then. | Director/Board Member | 01.01.2010 |
Ausbildung von Jessie English
Kansas State University | Undergraduate Degree |
The University of North Carolina at Chapel Hill | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SENSEI BIOTHERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
ArQule, Inc.
ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
IRBM SpA
IRBM SpA BiotechnologyHealth Technology IRBM SpA is a research organization that specializes in drug discovery and development. IRBM is based in Pomezia, IT, and has subsidiaries in Italy. The Italian company produces recombinant proteins in a homogeneous state and use cyclization to pre-organize compounds for target binding. The private company uses nuclear magnetic resonance (NMR) spectroscopy to study structural biology, clinical research solutions, functional genomics, structure/activity relationships, drug discovery, macromolecule, and small-molecule analysis. The company has a screening library of over 320,000 compounds and use virtual screening and NMR to drive innovation. The company was founded in 2010 by Piero di Lorenzo, who has been the CEO since then. | Health Technology |
Tilos Therapeutics, Inc.
Tilos Therapeutics, Inc. BiotechnologyHealth Technology Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA. | Health Technology |
Belfer Center for Applied Cancer Science
Belfer Center for Applied Cancer Science Miscellaneous Commercial ServicesCommercial Services The Belfer Center for Applied Cancer Science operates a cancer research center. The non-profit company is based in Boston, MA. | Commercial Services |
Bakx Therapeutics, Inc.
Bakx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bakx Therapeutics is a company based in DE that focuses on developing more effective and precise therapeutics that utilize the mitochondrial apoptosis pathway. The American company's proprietary codynx™ drug discovery platform integrates computational and experimental capabilities to collaborate with researchers in validated biological pathways. Bakx's leading asset, partnered with Ipsen, is focused on activating the bax protein to treat cancer and age-related diseases. Bakx Therapeutics, Inc. was co-founded by world-leading researchers in apoptosis and computationally aided drug discovery. Sree Kant has been the CEO of the company since 2020. | Health Technology |